| Progression-free survival | Overall survival | ||||||
---|---|---|---|---|---|---|---|---|
 | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||||
Variables | HR (95 % CI) | p-value | HR (95 % CI) | p-value | HR (95 % CI) | p-value | HR (95 % CI) | p-value |
Age (years) | ||||||||
 ≥51 vs. <51 | 0.51 (0.17–1.42) | 0.20 |  |  | 0.71 (0.20–2.35) | 0.57 |  |  |
FIGO stage | ||||||||
 I vs. II, III, IV | 0.11 (0.04–0.32) | < 0.01 | 0.12 (0.02–0.61) | 0.01 | 0.06 (0.01–0.22) | < 0.01 | 0.09 (0.01–0.84) | 0.04 |
Residual tumor at PDS | ||||||||
 Optimal vs. Suboptimal | 0.17 (0.06–0.50) | < 0.01 | 0.95 (0.20–3.55) | 0.94 | 0.09 (0.02–0.29) | < 0.01 | 0.37 (0.05–1.68) | 0.21 |
Invasive pattern | ||||||||
 Infiltrative invasion vs. Expansile invasion | 8.69 (2.37–55.86) | < 0.01 | 9.01 (2.28–61.41) | < 0.01 | 12.52 (2.37-230.59) | < 0.01 | 17.56 (2.58-393.24) | < 0.01 |